公开(公告)号：US09869668B2

公开(公告)日：2018-01-16

申请号：US14836596

申请日：2015-08-26

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

Inventor： Jae Hyun Choi ,  Kyung Ah Kim ,  Youngwook Kim ,  Keunchil Park

IPC: G01N33/50

CPC classification number: G01N33/5011 ,  G01N2333/49 ,  G01N2800/52

Abstract: Provided is a method for evaluating efficacy of, or resistance to, a c-Met targeting agent including measuring a level of a PDGF protein and/or a PDGF coding gene.

公开(公告)号：US09567641B2

公开(公告)日：2017-02-14

申请号：US14323642

申请日：2014-07-03

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  GEORGETOWN UNIVERSITY

Inventor： Bo Gyou Kim ,  Shangzi Wang ,  Ji Min Lee ,  Kyung Ah Kim ,  Louis M. Weiner

IPC: A61K39/395 ,  C12Q1/68 ,  A61K45/06 ,  A61K38/18 ,  G01N33/50 ,  C07K16/28 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17

CPC classification number: C12Q1/6886 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1774 ,  A61K38/1808 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2836 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5023 ,  G01N2800/52 ,  A61K2300/00

Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Abstract translation: 用于与抗c-Met抗体组合治疗的靶物质，用于预防和/或治疗癌症的组合用药物组合物，包括抗c-Met抗体和针对所述靶物质的抑制剂作为活性成分的方法 用于预防和/或治疗癌症，包括共同施用抗c-Met抗体和针对靶物质的抑制剂，以及使用目标物质筛选用于预防和/或治疗癌症的药物的方法。

公开(公告)号：US09556275B2

公开(公告)日：2017-01-31

申请号：US14244709

申请日：2014-04-03

Applicant: Samsung Electronics Co., Ltd.

Inventor： Yun Ju Jeong ,  Kyung Ah Kim ,  Kyung Eun Kim ,  Chungho Kim

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/22

CPC classification number: C07K16/2863 ,  A61K2039/507 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Abstract translation: 一种抑制血管生成和治疗血管发生相关疾病的方法，包括同时或依次给予抗c-Met抗体或其抗原结合片段，以及抗Ang-2抗体或其抗原结合片段; 以及相关的组合物和方法。

公开(公告)号：US20160144028A1

公开(公告)日：2016-05-26

申请号：US14949303

申请日：2015-11-23

Applicant: Samsung Electronics Co., Ltd.

Inventor： Jimin Lee ,  Bo Gyou Kim ,  Seungja Oh ,  Kyung Ah Kim ,  Powei Lin ,  Saet Byoul Lee

IPC: A61K39/395 ,  G01N33/574 ,  A61K31/4985

CPC classification number: A61K39/39558 ,  A61K31/00 ,  A61K31/4985 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  G01N33/57492 ,  G01N33/74 ,  G01N2333/65 ,  G01N2800/52

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor

Abstract translation: 一种预防和/或治疗癌症的方法，所述方法包括将c-Met和EGFR双重抑制剂（以下称为“c-Met / EGFR双重抑制剂”）和IGF-1R抑制剂共同给予需要的受试者 并且使用IGF-1R作为对c-Met / EGFR双重抑制剂的抗性的标记物

公开(公告)号：US20160090635A1

公开(公告)日：2016-03-31

申请号：US14869563

申请日：2015-09-29

Applicant: Samsung Electronics Co., Ltd.

Inventor： Seon Hui Shim ,  Soo Yeon Jung ,  Kyung Ah Kim

IPC: C12Q1/68 ,  C07K16/30 ,  C07K16/40

Abstract: A method for predicting and/or monitoring the efficacy of a c-Met inhibitor using a biomarker; a method for selecting a subject suitable for the application of a c-Met inhibitor using a biomarker; and a method for preventing and/or treating cancer comprising administering a c-Met inhibitor to the selected subject.

Abstract translation: 使用生物标志物预测和/或监测c-Met抑制剂的功效的方法; 用于使用生物标志物选择适合于应用c-Met抑制剂的受试者的方法; 以及用于预防和/或治疗癌症的方法，包括向所选择的受试者施用c-Met抑制剂。

公开(公告)号：US09233155B2

公开(公告)日：2016-01-12

申请号：US14242638

申请日：2014-04-01

Applicant: Samsung Electronics Co., Ltd.

Inventor： Bo Gyou Kim ,  Ji Min Lee ,  Kyung Ah Kim ,  Yun Ju Jeong

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/4412 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K31/4412 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92 ,  A61K2300/00

Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.

Abstract translation: 本发明提供了一种预防或治疗癌症的组合疗法，包括或主要由对象给予索拉非尼和抗c-Met抗体或其抗原结合片段。 联合治疗方法可以达到优异的协同效应，降低抗c-Met抗体的有效剂量，从而实现更有效的癌症治疗。

公开(公告)号：US09213031B2

公开(公告)日：2015-12-15

申请号：US13949012

申请日：2013-07-23

Applicant: SAMSUNG ELECTRONICS CO., LTD.

Inventor： Ji Min Lee ,  Kyung Ah Kim ,  Bo Gyou Kim ,  Young Mi Oh ,  Saet Byoul Lee ,  Yun Ju Jeong

IPC: C12Q1/68 ,  G01N33/53 ,  G01N33/574 ,  C07K16/30 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: G01N33/57492 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2800/52 ,  A61K2300/00

Abstract: A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.

Abstract translation: 一种鉴定细胞样本或适合于用抗c-Met抗体或其抗原结合片段治疗的受试者的方法，所述抗c-Met抗体或其抗原结合片段通过测定Cbl浓度特异性地结合c-Met蛋白质的SEMA结构域中的表位，Cbl 突变和/或与受试者的细胞样品中与Cbl相互作用的c-Met位点的突变，以及相关的组合物和方法。

公开(公告)号：US20140294830A1

公开(公告)日：2014-10-02

申请号：US14227759

申请日：2014-03-27

Applicant: SAMSUNG LIFE WELFARE FOUNDATION ,  SAMSUNG ELECTRONICS CO., LTD.

Inventor： Saet Byoul LEE ,  Jae Hyun Choi ,  Kyung Ah Kim ,  Ji Min Lee ,  Yun Ju Jeong

IPC: A61K39/395 ,  A61K31/5377 ,  A61K31/517

CPC classification number: A61K39/3955 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/00 ,  A61K2300/00

Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Abstract translation: 用于预防和/或治疗c-Met-和/或EGFR诱导的疾病的组合疗法的方法，包括将药学有效量的EGFR拮抗剂和药学上有效量的抗c-Met抗体共同施用于 提供了有需要的受试者。

公开(公告)号：US09956244B2

公开(公告)日：2018-05-01

申请号：US14814278

申请日：2015-07-30

Applicant: Samsung Electronics Co., Ltd.

Inventor： Ji Min Lee ,  Bo Gyou Kim ,  Seung Ja Oh ,  Kyung Ah Kim ,  Saet Byoul Lee ,  Jae Woong Hwang

IPC: G01N33/50 ,  G01N33/574 ,  A61K31/713 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

CPC classification number: A61K31/713 ,  A61K39/39533 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57484 ,  G01N2800/52 ,  A61K2300/00 ,  A61K31/573

Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.

公开(公告)号：US09943596B2

公开(公告)日：2018-04-17

申请号：US14949303

申请日：2015-11-23

Applicant: Samsung Electronics Co., Ltd.

Inventor： Jimin Lee ,  Bo Gyou Kim ,  Seungja Oh ,  Kyung Ah Kim ,  Powei Lin ,  Saet Byoul Lee

IPC: A61K39/395 ,  A61K31/4985 ,  G01N33/574 ,  A61K31/00 ,  C07K16/28 ,  G01N33/74 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K31/00 ,  A61K31/4985 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  G01N33/57492 ,  G01N33/74 ,  G01N2333/65 ,  G01N2800/52

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.